April 25, 2018 / 8:35 PM / 7 months ago

BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros

April 25 (Reuters) - GALAPAGOS NV:

* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO

* Q1 OPERATING LOSS EUR 32.0 MILLION VERSUS LOSS OF EUR 11.2 MILLION YEAR AGO

* Q1 NET LOSS FOR THE PERIOD EUR 37.3 MILLION VERSUS LOSS OF EUR 13.6 MILLION YEAR AGO

* CASH AND CASH EQUIVALENT AT END-Q1 EUR 1.11 BILLION VERSUS EUR 0.95 BILLION YEAR AGO

* AIMS TO REPORT TOPLINE RESULTS WITH FINCH 2 (RHEUMATOID ARTHRITIS) AND EQUATOR (PSORIATIC ARTHRITIS) IN 2018

* AIMS TO REPORT TOPLINE RESULTS WITH TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB STUDY IN 2018

* IN 2018, AIMS TO REPORT DECISION TO CONTINUE TO PHASE 3 IN SELECTION (ULCERATIVE COLITIS)

* IN 2018, CO’S PARTNER GILEAD TO COMPLETE RECRUITMENT OF REMAINING RA PHASE 3 STUDIES WITH FILGOTINIB

* IN 2018, FOR CYSTIC FIBROSIS, EXPECTS READOUT OF PELICAN PATIENT STUDY WITH GLPG2737

* IN 2018, FOR CYSTIC FIBROSIS, EXPECTS INTERIM READOUT WITH FIRST TRIPLE COMBINATION THERAPY IN FALCON

* TO START DOSING ISABELA LATER IN 2018

* TO INITIATE PHASE 2 STUDIES WITH GLPG1205 (IPF), ADDITIONAL CF TRIPLE COMBINATION, GLPG1972 (OSTEOARTHRITIS), AND MOR106 (ATOPIC DERMATITIS) LATER IN 2018

* EXPECTS OPERATIONAL CASH BURN BETWEEN EUR 220 MILLION AND EUR 240 MILLION IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below